Activity of tesetaxel, an oral taxane, given as a single-agent in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC) in a phase 2 study.

Authors

Andrew David Seidman

Memorial Sloan Kettering Cancer Center, New York, NY

Andrew David Seidman , Lee Steven Schwartzberg , Vinay K. Gudena , Peter Rubin , Stew Kroll , Joseph P. O'Connell , Kevin Tang , Joyce O'Shaughnessy

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane.

First Author: Joyce O'Shaughnessy

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Contessa: A multinational, multicenter, randomized, phase 3 registration study of tesetaxel in patients (Pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (MBC).

First Author: Joyce O'Shaughnessy

insert_chart_outlined

Poster

2021 ASCO Annual Meeting

bookmark_border

Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.

First Author: Lee S. Schwartzberg

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC).

First Author: Erica L. Mayer